Building strong collaborative relationships is fundamental to the development of any drug or healthcare company. Our aim is to couple the Syntopix scientific and research capabilities with the late stage development and marketing expertise of our chosen partners.
We aim to be your partner of choice by offering:
03/02/2010 07:00
Syntopix announces a Directorate change with Tom Bannatyne joining as Chairman.
12/11/2009 07:00
Syntopix announces positive results for its lead dermatological compound SYN0126
12/11/2009 07:00
Syntopix focuses development efforts around three specific core compounds
14/04/2009 13:13
EXCLUSIVE EVALUATION AGREEMENT
Syntopix signs an exclusive evaluation agreement with a major consumer healthcare company..